#USA #Cambridge #Nona Biosciences #Valink Therapeutics #Biologics Research

Strategic Alliance to Propel Drug Discovery

In a significant move for the biotechnology sector, Nona Biosciences and Valink Therapeutics have formed a strategic alliance aimed at accelerating the discovery of novel biologics. This collaboration, branded as "Biology to Bispecific" (B2B)™, is set to combine the advanced technical platforms and expertise of both companies to drive innovation in the field of bispecific antibodies and antibody-drug conjugates (ADCs).

Nona Biosciences: A Leader in Biotherapeutics

Nona Biosciences is well-recognized in the global biotech landscape for its robust solutions that span the entire drug development process from 'Idea to IND' (I to I®). The company has previously supported over 300 drug discovery initiatives across various therapeutic areas, establishing a reputation as a pioneer in biotherapeutics innovation. Nona’s proprietary Harbour Mice® platform is a game-changer, generating fully human monoclonal antibodies that offer extraordinary versatility for complex biologics applications, such as bispecific antibodies and CAR-T therapies.

Valink Therapeutics: Pioneering New Therapeutic Modalities

On the other side of the alliance sits Valink Therapeutics, a private biotech firm dedicated to developing next-generation therapeutics with a special emphasis on bispecific ADCs. Valink’s LiliumX™ discovery platform boasts the potential to generate and functionally screen complex drug candidates from antibody fragments, giving it a unique edge in the exploration of biologics. The focus on bispecific antibodies manifests through Valink’s V-gate™ strategy, which aims to enhance targeting strategies and target-pair synergies.

Combining Strengths for Accelerated Drug Development

The collaboration between Nona and Valink will harness the strengths of both companies to fast-track the creation of drug candidates. The partnership will leverage Nona's extensive library of fully human antibodies, including its innovative heavy chain-only antibodies (HCAbs), to complement Valink's high-throughput LiliumX™ platform. The initial project will emphasize bispecific ADCs aimed at treating solid tumors, an area presenting significant unmet medical needs.

Dr. Di Hong, CEO of Nona Biosciences, expressed excitement over the collaboration, stating: "By uniting our industry-leading antibody technology platforms, we aim to accelerate the pace of bispecific antibody and bsADC discovery and development, ultimately delivering transformative therapies to patients in oncology and beyond." Similarly, Dr. Arne Scheu, CEO of Valink Therapeutics, noted the strategic fit, mentioning that this partnership enhances their capacity to develop impactful therapies for patients.

The Road Ahead for Biologics Discovery

As the biotech landscape continues to evolve, collaborations such as the one between Nona and Valink signify a forward-thinking approach to drug discovery. The unique combination of their respective technologies is likely to result in substantial advancements in the field of biologics, particularly in the development of tailored therapies that could greatly improve patient outcomes.

Both companies are committed to advancing the research and development of innovative therapeutics that address critical medical challenges. With this strategic alliance, Nona Biosciences and Valink Therapeutics are set to make waves in the biotechnology sector, potentially leading to groundbreaking treatments for various conditions, starting with solid tumors.

For more information about their groundbreaking partnership and progress in drug discovery, interested individuals can visit Nona Biosciences and Valink Therapeutics.